招商证券股份有限公司 关于江苏硕世生物科技股份有限公司 使用闲置募集资金进行现金管理的核查意见 招商证券股份有限公司（以下简称"保荐机构"、"招商证券"）作为江苏 硕世生物科技股份有限公司（以下简称"硕世生物"、"公司"、"发行人"） 首次公开发行股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股 票上市规则》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》、《上海证券交易所上市公司募集资金管理办法（2013 年修订）》、《科创 板上市公司持续监管办法（试行）》等法律、行政法规、部门规章及业务规则， 对公司拟使用闲置募集资金进行现金管理的事项进行了审慎核查，核查意见如 下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意江苏硕世生物科技股份有限公司首 次公开发行股票注册的批复》(证监许可[2019]2224 号)和上海证券交易所自律监 管决定书[2019]267 号核准同意，公司首次公开发行人民币普通股 1,466 万股， 发行价格 46.78 元/股，新股发行募集资金总额为 68,579.48 万元, 扣除发行费用 7,286.12 万元后, 募集资金净额为 6 ...

证券代码：688399 证券简称：硕世生物 公告编号：2023-034 江苏硕世生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）近日 收到国家药品监督管理局(以下简称"国家药监局")签发的医 疗器械注册证（体外诊断试剂）,具体信息如下: 一、医疗器械注册证的具体情况 力。 三、风险提示 | 序 | 产品名称 | 注册编号 | 注册证有 | 注册分类 | 预期用途 | | | --- | --- | --- | --- | --- | --- | --- | | 号 | | | 效期 | | 本产品用于体外 | | | 1 | 诺如病毒核酸检测 | 国械注准 | 至二〇二八 | 三类 | 定性检测粪便样 | | | | 试剂盒（荧光 法） PCR | 20233401439 | 年十月八日 | | 本中诺如病毒 GI | | | | | | | | 和 GII 型核酸 | RNA | 二、对公司的影响 上述《医疗器械 ...

江苏硕世生物科技股份有限公司（以下简称"公司"）于近 日收到招商证券股份有限公司（以下简称"招商证券"）出具的 《关于更换保荐代表人的函》。招商证券作为公司首次公开发行 股票并在科创板上市的保荐机构，原指定保荐代表人王炳全先生、 王志伟先生履行持续督导职责，现因王炳全先生工作调整，不再 负责对公司的持续督导工作。为保证持续督导工作的有序进行， 招商证券委派彭翼先生（简历附后）接替王炳全先生的持续督导 工作，履行保荐职责。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 证券代码：688399 证券简称：硕世生物 公告编号：2023-030 江苏硕世生物科技股份有限公司 关于更换保荐代表人的公告 彭翼先生：保荐代表人，中国注册会计师非执业会员，南京 大学气象学硕士，曾主持或参与国博电子科创板 IPO、硕世生物 科创板 IPO、蒙娜丽莎 IPO 以及创意信息重大资产重组等项目， 具有丰富的投资银行工作经验。 本次变更后，公司首次公开发行股票持续督导的保荐代表人 为王志伟先生和彭翼先生，持续督导期至中国证券监督管理委员 会和上 ...

江苏硕世生物科技股份有限公司 2023 年第一次临时股东大会会议材料 证券简称：硕世生物 证券代码：688399 江苏硕世生物科技股份有限公司 2023 年第一次临时股东大会会议材料 2023 年 9 月 19 日 江苏硕世生物科技股份有限公司 2023 年第一次临时股东大会会议材料 江苏硕世生物科技股份有限公司 2023 年第一次股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司股东大会规则》以及《江苏硕世生物科技股份有限公司章程》、《江苏 硕世生物科技股份股份有限公司股东大会议事规则》等相关规定，特制定 2023 年第一次临时股东大会须知。 江苏硕世生物科技股份有限公司 2023 年第一次临时股东大会会议材料 股东及股东代理人违反上述规定，会议主持人有权予以拒绝或制止。 七、主持人可安排公司董事、监事、高级管理人员回答股东所提问题，对于 可能将泄露公司商业秘密及/或内部信息，损害公司、股东共同利益的提问，主 持人或其指定的有关人员有权拒绝回答。 八、出席股东大会的股东及股东代理人，应当对 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company projects a revenue guidance of RMB 1.2 billion for the full year 2023, indicating a 15% growth from the previous year[1]. - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2023, representing a 25% year-over-year growth[14]. - The company reported a total revenue of 855 million RMB for the first half of 2023, with a year-on-year increase of 7.85%[48]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q2 2023, representing a 25% year-over-year growth[109]. - The company provided an optimistic outlook for the next quarter, projecting a revenue increase of 20% to 1.8 billion[109]. - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 30%[14]. - The company reported a significant drop in R&D expenses, totaling CNY 68.77 million, down 34.84% from the previous year[68]. User Growth - User data indicates a growth in active users to 1.2 million, up from 1 million in the previous half-year, marking a 20% increase[1]. - User data indicates that the active user base has expanded to 1.2 million, marking a 30% increase compared to the previous year[14]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous quarter[109]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous year[112]. Product Development and Innovation - New product launches include two innovative diagnostic kits expected to contribute an additional RMB 100 million in revenue by the end of 2023[1]. - New product launches are expected to contribute an additional 100 million RMB in revenue by the end of 2023[14]. - The company is focusing on expanding its product offerings in the molecular diagnostics sector, which is experiencing significant demand growth[28]. - The company is focusing on the development of integrated diagnostic products, including a new HPV detection system and tumor precision diagnosis tools[48]. - The company is actively pursuing partnerships with international giants and entering the third-party testing field to enhance its market position[33]. - The company has launched products in the POCT field, including antigen testing kits for influenza A/B, which have already generated revenue[99]. - The company is focusing on obtaining EU CE certification for its reagent products to expand into Southeast Asia and European markets, effectively utilizing new production capacity[100]. Research and Development - Research and development expenses increased by 25% to RMB 80 million, focusing on molecular diagnostics technology[1]. - The company's R&D expenditure as a percentage of operating revenue increased by 33.62%, reaching 36.85% in the first half of 2023[21]. - The company is investing heavily in R&D, with a budget allocation of 200 million for new technology development in 2023[109]. - The company has a strong focus on R&D, with ongoing projects aimed at enhancing the sensitivity and specificity of diagnostic technologies[46]. - The company is focusing on enhancing its R&D capabilities and market expansion strategies, with a commitment to continuous investment in research and development to maintain its competitive edge[99]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[1]. - Market expansion efforts include entering three new international markets, aiming for a 10% increase in market share[14]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[113]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotechnology sector[14]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 500 million allocated for potential deals[111]. Financial Health and Risks - The company's operating revenue for the first half of 2023 was ¥186.61 million, a decrease of 94.29% compared to ¥3.27 billion in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2023 was -¥68.29 million, down 105.54% from ¥1.23 billion in the previous year[20]. - The net cash flow from operating activities decreased by 145.71%, amounting to -¥389.31 million, compared to ¥851.74 million in the same period last year[20]. - The company faces risks related to the management of distributors, which could impact regional sales if not properly managed[62]. - The decline in revenue is mainly attributed to a significant drop in sales of COVID-related products and services[68]. - The company has reported strong growth in its non-COVID related business despite a significant decline in overall performance due to reduced demand for COVID products[54]. Governance and Compliance - The board of directors confirmed that all members attended the meeting, ensuring accountability for the report's accuracy[1]. - There are no violations of decision-making procedures regarding external guarantees[1]. - The company has no significant non-operating fund occupation by controlling shareholders or related parties[1]. - The company has established a performance and incentive system to enhance operational efficiency and ensure personnel stability[57]. - The company has committed to fulfilling all promises made during its public offering and will accept supervision from regulatory authorities and investors[98]. Shareholder Information - The company has established a commitment to not reduce shareholdings during significant legal or regulatory issues that could lead to delisting[92]. - The company will disclose the reasons for any share reduction, the intended quantity, and the impact on governance and operational continuity[93]. - The company has established a three-year shareholder return plan post-listing, which includes cash and stock dividends based on profitability and cash flow conditions[105]. - The company plans to distribute cash dividends of at least 10% of the distributable profits if there are no major investment plans or cash expenditures in the next 12 months[102]. - The company has not reported any significant changes in its stock ownership structure during the reporting period[135].

证券代码：688399 证券简称：硕世生物 公告编号：2023-029 江苏硕世生物科技股份有限公司 关于参加2023 半年度制药及生物制品行业 集体业绩说明会的公告 重要内容提示： （http://roadshow.sseinfo.com/） 投资者可于 2023 年 9 月 6 日(星期三)16:00 前通过邮件、电话等形式将需 要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关注的 问题进行回答。 江苏硕世生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日 发布公司 2023 半年度报告，为便于广大投资者更全面深入地了解公司 2023 半年度 经营成果、财务状况、发展理念，公司参与了由上交所主办的 2023 半年度制药及 生物制品行业集体业绩说明会，此次活动将采用视频和网络文字互动的方式举行， 投资者可登录上海证券交易所上证路演中心（http://roadshow.sseinfo.com/）参 与线上互动交流。 一、 说明会类型 本次投资者说明会以视频和网络互动形式召开，公司将针对 2023 半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 ...

江苏硕世生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 证券代码：688399 证券简称：硕世生物 公告编号：2023-022 江苏硕世生物科技股份有限公司（以下简称"公司"）近日 收到国家药品监督管理局(以下简称"国家药监局")签发的医 疗器械注册证（体外诊断试剂）,具体信息如下: 二、对公司的影响 上述《医疗器械注册证》的取得，丰富了公司产品种类，扩 充了公司在体外诊断领域的布局，不断满足多元化的临床需求， 将增强公司综合竞争力，有利于进一步提高公司的市场拓展能 力。 三、风险提示 1 江苏硕世生物科技股份有限公司董事会 2023 年 8 月 12 日 2 一、医疗器械注册证的具体情况 序号 产品名称 注册编号 注册证 有效期 注册 分类 预期用途 1 EB 病毒核酸检测试 剂盒（荧光 PCR 法） 国械注准 20233401154 至 2028 年 8 月 9 日 三类 本试剂盒适用于体外定量 检测外周血样本中 EB 病毒 DNA 上述产品获证后的实际销售 ...

证券代码：688399 证券简称：硕世生物 公告编号：2023-015 江苏硕世生物科技股份有限公司 关于参加 2022 年度体外诊断专场 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 06 月 12 日(星期一)下午 14:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心（网 址：https://roadshow.sseinfo.com/） 投资者可于 2023 年 6 月 9 日(星期五)17:00 前通过邮件方式将 需要了解和关注的问题发送至公司邮箱 sssw@s-sbio.com，公司将在 文字互动环节对投资者普遍关注的问题进行回答。 江苏硕世生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年年度报告，为加强与投资者的深入交 流，使投资者更加全面、深入地了解公司情况，公司参与了由上海证 券交易所主办的 2022 年度体外诊断专场集体业绩说明会，欢迎 ...

证券代码：688399 证券简称：硕世生物 公告编号： 2023-013 江苏硕世生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 （二） 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 05 月 09 日(星期二) 至 05 月 15 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 sssw@s-sbio.com 进行提问。公司将在说明会上对投资者 普遍关注的问题进行回答。 江苏硕世生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年年度报告及 2023 年第一季度报告，为 便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季 度经营成果、财务状况，公司计划于 2023 年 0 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥94,053,695.57, representing a decrease of 93.82% compared to the same period last year[2] - The net profit attributable to shareholders was -¥19,424,028.96, a decline of 103.08% year-over-year[2] - Basic and diluted earnings per share were both -¥0.33, reflecting a decrease of 103.06%[2] - Total revenue for Q1 2023 was CNY 94,053,695.57, a significant decrease of 93.83% compared to CNY 1,521,902,378.62 in Q1 2022[15] - Net profit for Q1 2023 was a loss of CNY 19,424,028.96, compared to a profit of CNY 631,070,096.78 in Q1 2022, indicating a decline of 103.08%[16] Cash Flow - The net cash flow from operating activities was -¥226,392,877.94, down 146.17% from the previous year[2] - In Q1 2023, the net cash flow from operating activities was -226,392,877.94, a significant decline compared to 490,379,975.90 in Q1 2022[19] - The total cash outflow from operating activities was 497,068,809.17, compared to 866,900,896.52 in the same quarter last year[19] - Cash inflow from sales and services received was 214,177,789.24, a decrease from 1,334,170,582.58 in Q1 2022[18] - The total cash and cash equivalents at the end of Q1 2023 were 979,636,103.79, down from 1,062,017,901.88 at the end of Q1 2022[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,715,437,080.57, a decrease of 3.59% from the end of the previous year[3] - Total liabilities as of Q1 2023 amounted to CNY 956,710,813.88, down from CNY 1,112,849,694.21 in the previous year, a reduction of 14.06%[15] - The equity attributable to shareholders was ¥3,758,726,266.69, down 0.51% compared to the previous year[3] - The company's total assets as of March 31, 2023, were ¥4,715,437,080.57, down from ¥4,890,999,989.86, representing a decrease of approximately 3.6%[13] Research and Development - Research and development expenses totaled ¥34,288,082.49, which is an increase of 26.29% year-over-year, accounting for 36.46% of operating revenue, up 34.68 percentage points[2] - Research and development expenses for Q1 2023 were CNY 34,288,082.49, an increase of 26.00% compared to CNY 27,149,529.76 in Q1 2022[16] Investment Activities - Total cash inflow from investment activities reached 2,114,275,580.39, up from 517,215,844.18 in the same period last year[19] - The cash outflow from investment activities was 2,324,226,649.49, compared to 619,363,626.32 in Q1 2022, resulting in a net cash flow from investment activities of -209,951,069.10[19] Shareholder Information - The company has a total of 15,600,000 shares held by its largest shareholder, accounting for 26.61% of the total shares[10] Other Information - The significant decline in revenue was primarily due to a sharp decrease in income from COVID-related products and services[6] - The company has not disclosed any significant new strategies or product developments during the reporting period[11] - The company has not disclosed any new product developments or market expansion strategies in the provided financial report[17]